Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ironwood Pharma ( (IRWD) ) has issued an announcement.
On March 10, 2026, Ironwood Pharmaceuticals notified the administrative agent under its existing revolving credit agreement that it had satisfied the liquidity conditions specified in the contract’s definition of the maturity date. As a result, the maturity date for Ironwood’s revolving credit facility remains December 31, 2028, which helps preserve the company’s access to committed capital and supports financial flexibility for its ongoing operations and strategic plans.
The most recent analyst rating on (IRWD) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
Spark’s Take on IRWD Stock
According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.
The score is driven primarily by mixed fundamentals: strong cash flow and improved 2025 profitability are weighed down by negative equity and weakening revenue. Technicals add pressure due to a weak near-term trend, while the earnings call supports the outlook with upbeat 2026 guidance and a deleveraging path; valuation is middling with no dividend support.
To see Spark’s full report on IRWD stock, click here.
More about Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a biopharmaceutical company that operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for gastrointestinal and other specialty conditions. The company’s business model relies on access to capital and credit facilities to support its operations, research programs, and potential growth initiatives.
Average Trading Volume: 4,542,835
Technical Sentiment Signal: Sell
Current Market Cap: $603.3M
For a thorough assessment of IRWD stock, go to TipRanks’ Stock Analysis page.